BLASUBCUTANEOUSINJECTABLE
Approved
Aug 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FOLLISTIM AQ is a recombinant follicle-stimulating hormone (FSH) indicated for ovulation induction and assisted reproductive technologies. Administered subcutaneously, it stimulates follicle development in women undergoing fertility treatment. The product represents a foundational therapy in reproductive endocrinology.
LOE Approaching
Product lifecycle is nearing LOE, signaling potential team restructuring and a shift toward lifecycle extension or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on FOLLISTIM AQ offers stability in a specialized therapeutic area (reproductive health) with deep HCP relationships, but faces transition risk due to approaching LOE. Career growth depends on driving market access, patient support programs, and biosimilar defense strategies.
Brand ManagerMedical Science Liaison (MSL)
Worked on FOLLISTIM AQ at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.